Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy targets tough lymphoma in early trial

NCT ID NCT06139406

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This early-phase study tests a new drug (JNJ-87801493) combined with immune-activating therapies (T-cell engagers) in about 70 people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to other treatments. The main goals are to check safety and find the best dose. The trial is not yet recruiting and is actively ongoing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
JNJ-87801493 combined with T-cell engagers (JNJ-80948543 or JNJ-75348780)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat B-cell non-Hodgkin lymphoma.
What could go wrong
This is a very early (Phase 1) and small (70 participants) trial focused on safety, not yet on effectiveness. The combination may cause serious side effects like cytokine release syndrome, and it may not work for many patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, NON-HODGKIN

Contacts and locations

Locations

  • Austin Hospital

    Heidelberg, 3084, Australia

  • Clinica Univ. de Navarra

    Pamplona, 31008, Spain

  • Hadassah Medical Center

    Jerusalem, 9112001, Israel

  • Hosp Clinico Univ de Salamanca

    Salamanca, 37007, Spain

  • Hosp Univ Fund Jimenez Diaz

    Madrid, 28040, Spain

  • Hosp Univ Vall D Hebron

    Barcelona, 08035, Spain

  • Linear Clinical Research Ltd

    Nedlands, 6009, Australia

  • Odense University Hospital

    Odense, 5000, Denmark

  • Rigshospitalet

    Copenhagen, DK-2100, Denmark

  • Scientia Clinical Research

    Randwick, 2031, Australia

  • Sourasky (Ichilov) Medical Center

    Tel Aviv, 6423906, Israel

  • The Alfred Hospital

    Melbourne, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.